Annuradha Bhandari, MD
Internal Medicine · Richmond, INNPI 1568777092
Payments from drug & device makers
Across 162 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$625
- GSK$523
- Novo Nordisk$153
- AstraZeneca$149
- Portola Pharmaceuticals, LLC$137
- Abbott$84
- plus $776 from 25 others
What the payments were for
- Food & beverage$2,39798%
- Other$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $625 |
| GSK | 45 | $523 |
| Novo Nordisk | 10 | $153 |
| AstraZeneca | 10 | $149 |
| Portola Pharmaceuticals, LLC | 1 | $137 |
| Abbott | 3 | $84 |
| Novartis | 5 | $83 |
| Lilly USA, LLC | 4 | $78 |
| Daiichi Sankyo Inc. | 4 | $76 |
| Johnson & Johnson | 5 | $75 |
| Bayer | 2 | $43 |
| Zealand Pharma US, Inc. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $37 |
| Mannkind Corporation | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Inari Medical, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Vertex | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Merck | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| VBI Vaccine (delaware) Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Medtronic | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$137
How this compares
$2,447 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $103,095 |
| EliquisApixaban | 49 | $61,745 |
| JardianceEmpagliflozin | 63 | $61,596 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $38,687 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $38,202 |
| FarxigaDapagliflozin Propanediol | 31 | $24,313 |
| LinzessLinaclotide | 13 | $19,930 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $15,996 |
| VascepaIcosapent Ethyl | 13 | $13,202 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $10,050 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,350 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,758 |
| Dexlansoprazole DrDexlansoprazole | 33 | $6,408 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 103 | $6,226 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $6,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $153 | $103,09592 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $523 | $85,23997 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $18 | $68,35477 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $149 | $43,39163 claims |
| AbbVieLinzess, Namzaric, Synthroid | $625 | $27,71449 claims |
| Lilly USA, LLCHumalog Mix 75-25 | $78 | $2,00912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Richmond
- Alex GilmanRichmond$23K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.